Such trials, NCT05878912 and NCT05942287 [53,54], will generate important data on the benefit of GLP-1 RAs (and potentially) other interventions in obesity-related outputs unique to HFpEF populations. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.